Premalignant cervical lesions are characterized by dihydrofolate reductase gene amplification and c-Myc overexpression: Possible biomarkers

Journal of Lower Genital Tract Disease

Volumn 11, Issue 4, 2007, Pages 265-272

  Guijon, Fernando B ^a,d   Greulich Bode, K M ^b,c   Paraskevas, Maria ^a   Baker, Patricia ^a   Mai, Sabine ^b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d NONE   (Canada)

Author keywords

C Myc; Cervical cancer; Cervix; Dihydrofolate reductase (DHFR); Fluorescence in situ hybridization (FISH); Gene amplification; Quantitative fluorescent immunohistochemistry

Indexed keywords

BIOLOGICAL MARKER; DIHYDROFOLATE REDUCTASE; MYC PROTEIN;

ARTICLE; CANCER GRADING; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE LOCUS; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENOMIC INSTABILITY; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; ONCOGENE C MYC; PRECANCER; STATISTICAL SIGNIFICANCE; UTERINE CERVIX BIOPSY; UTERINE CERVIX CARCINOMA IN SITU;

CERVICAL INTRAEPITHELIAL NEOPLASIA; COLPOSCOPY; CYTOGENETIC ANALYSIS; FEMALE; FROZEN SECTIONS; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; PROTO-ONCOGENE PROTEINS C-MYC; TETRAHYDROFOLATE DEHYDROGENASE; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 34948860536     PISSN: 10892591     EISSN: None     Source Type: Journal    
DOI: 10.1097/LGT.0b013e31803c4df0     Document Type: Article

References (31)

1. Nesbit CE, Tersak JM, Prochownik EV. MYC oncogenes and human neoplastic disease. Oncogene 1999;18:3004-16.
2. Mai S, Mushinski JF. c-Myc-induced genomic instability. J Environ Pathol Toxico Oncol 2003;22:179-99.
3. Felsher DW, Bishop JM. Transient excess of MYC activity can elicit genomic instability and tumorigenesis. Proc Natl Acad Sci U S A 1999;96:3940-4.
4. Hidalgo A, Monroy A, Arana RM, Taja L, Vazquez G, Salcedo M. Chromosomal imbalances in four uterine cervix carcinoma derived cell lines. BMC Cancer 2003;3:8.
5. Harris CP, Lu XY, Narayan G, Singh B, Murty VV, Rao PH. Comprehensive molecular cytogenetic characterization of cervical cancer cell lines. Genes Chromosomes Cancer 2003;36:233-41.
6. Zhang A, Maner S, Betz R, Angstrom T, Stendahl U, Bergman F, et al. Genetic alterations in cervical carcinomas: frequent low-level amplifications of oncogenes are associated with human papillomavirus infection. Int J Cancer 2002;101:427-33.
7. Biscotti CV, O'Brien DL, Gero MA, Gramlich TL, Kennedy AW, Easley KA. Thin-layer Pap test vs conventional Pap smear. Analysis of 400 split samples. J Reprod Med 2002;47:9-13.
8. Fukasawa K, Wiener F, Vande Woude GF, Mai S. Genomic instability and apoptosis are frequent in p53 deficient young mice. Oncogene 1997;15:1295-02.
9. Aoyama C, Peters J, Senadheera S, Liu P, Shimada H. Uterine cervical dysplasia and cancer: identification of c-Myc status by quantitative polymerase chain reaction. Diagn Mol Pathol 1998;7:324-30.
10. Choo KB, Chong KY, Chou HF, Liew LN, Liou CC. Analysis of the structure and expression of c-Myc oncogene in cervical tumour and in cervical tumour-derived cell lines. Biochem Biophys Res Commun 1989;158:334-40.
11. Kersemaekers AM, Fleuren GJ, Kenter GG, Van den Broek LJ, Uljee SM, Hermans J, et al. Oncogene alterations in carcinomas of the uterine cervix: overexpression of the epidermal growth factor receptors is associated with poor prognosis. Clin Cancer Res 1999;5:577-86.
12. Riou G, Le MG, Favre M, Jeannel D, Bourhis J, Orth G. Human papillomavirus negative status and c-Myc gene overexpression: independent prognostic indicators of distant metastasis for early stage invasive cervical cancers. J Natl Cancer Inst 1992;84:1515-26.
13. Riou GF, Bourhis J, Le MG. The c-Myc protooncogene in invasive carcinomas of the uterine cervix: clinical relevance of overexpression in early stages of the cancer. Anticancer Res 1990;10:1225-31.
14. Bourhis J, Le MG, Barrois M, Gerbaulet A, Jeannel D, Duvillard P, et al. Prognostic value of c-Myc protooncogene overexpression in early invasive carcinoma of the cervix. J Clin Oncol 1990;8:1789-96.
15. Wu HJ. The expression of c-Myc protein in uterine cervical cancer: a possible prognostic indicator. Nippon Sanka Fujinka Gakkai Zasshi 1996;48:515-21.
16. Golijow CD, Abba MC, Mouron SA, Gomez MA, Culout FN. C-Myc gene amplification detected in preinvasive intraepithelial cervical lesions. Int J Gynecol Cancer 2001;11:462-5.
17. Ocadiz R, Sauceda R, Salcedo M, Ortega V, Rodriguez H, Gordillo C, et al. Occurrence of human papillomavirus type 16 DNA sequences and c-Myc oncogene alterations in uterine-cervix carcinoma. Arch Invest Med (Mex) 1989;20:355-62.
18. Dellas A, Schultheiss E, Holzgreve W, Oberholzer M, Torhorst J, Gudat F. Investigation of the bc12 and c-Myc expression in relationship to the Ki-67 labeling index in cervical intraepithelial neoplasia. Int J Gynecol Pathol 1997;16:212-8.
19. Iwasaka T, Yokoyama M, Oh-uchida M, Matsuo N, Hara K, Fukuyama K, et al. Detection of human papillomavirus genomes and analysis of expression of c-Myc and Ha-ras oncogenes in invasive cervical carcinomas. Gynecol Oncol 1992;46:298-303.
20. Sowani A, Ong G, Dische S, Quinn C, White J, Soutter P, et al. c-Myc oncogene expression and clinical outcome in carcinoma of the cervix. Mol Cell Probes 1989;3:117-23.
21. Slagle BL, Kaufman RH, Reeves WC, Icenogle JP. Expression of ras, myc, and p53 proteins in cervical intraepithelial neoplasia. Cancer 1998;83:1401-8.
22. Dellas A, Schultheiss E, Leivas MR, Moch H, Torhorst J. Association of p27Kip1, cyclin E and c-Myc expression with progression and prognosis in HPV-positive cervical neoplasmas. Anticancer Res 1998;18:3991-8.
23. Symonds RP, Habeshaw T, Paul J, Kerr DJ, Darling A, et al. No correlation between ras, c-Myc and c-jun protooncogene expression and prognosis in advanced carcinoma of cervix. Eur J Cancer 1992;28:1615-7.
24. Helm CW, Shrestha K, Thomas S, Shingleton HM, Miller DM. A unique c-Myc-targeted triplex-forming oligonucleotide inhibits the growth of ovarian and cervical carcinomas in vitro. Gynecol Oncol 1993;49:339-43.
25. Popescu NC, DiPaolo JA. Preferential sites for viral integration on mammalian genome. Cancer Genet Cytogenet 1989;42:157-71.
26. Couturier J, Sastre-Garau X, Schneider-Maunoury S, Labib A, Orth G. Integration of papillomavirus DNA near myc genes in genital carcinomas and its consequence for protooncogene expression. J Virol 1991;65:4534-8.
27. Ferber JM, Thorland EC, Brink AA, Rapp AK, Phillips LA, McGovern R, et al. Preferential integration of human papillomavirus type 18 near the c-Myc locus in cervical carcinoma. Oncogene 2003;22:7233-42.
28. Wani MA, Xu Y, Stambrook PJ. Increased methotrexate resistance and DHFR gene amplification as a consequence of induced Ha-ras expression in NIH3T3 cells. Cancer Res 1994;54:2504-8.
29. Goker E, Waltham M, Kheradpour A, Trippett T, Mazmdar M, Elisseyeff Y, et al. Amplification of the dihydrofolate reductase gene is a mechanism of acquired resistance to methotrexate in patients with acute lymphoblastic leukemia; and is correlated with p53 mutations. Blood 1995;86:677-84.
30. Lucke-Huhle C. Permissivity for methotrexate-induced DHFR gene amplification correlates with the metastatic potential of rat adenocarcinoma cells. Carcinogenesis 1994;14:695-700.
31. Nano R, Invernizzi R, Facoetti A, Raimondi E, Moralli D, Gerzeli G. Quantification of the DHFR gene in blast cells of leukemic patients by fluorescence in situ hybridization. Anticancer Res 2003;23:3883-7.